-
Nepali families hold symbolic funerals for missing after floods
-
Iran president offers US olive branch, hails Russian support
-
Newcastle sign Lille forward Fernandez-Pardo
-
TrustFinance Community Choice Awards 2026 Opens Global Voting
-
Even at Elysee, phones are handed in, Macron tells French pupils
-
Nepal disaster a climate 'warning signal': foreign minister
-
Chelsea agree to sign Atalanta's Ahanor, with Palace loan for this season
-
France winger Diaby returns to Leverkusen until 2031
-
Chelsea sign Atalanta's Ahanor and loan him to Palace
-
Barcelona confirm Jesus arrival from Arsenal
-
UK chalks up hottest summer on record for second year running
-
EU official says it's not time to 'normalize' Russia at G20 finance talks
-
China's Xi visits Egypt as US sanctions threat looms over Iran links
-
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®
-
RISE Robotics Awarded $100,000 MassVentures Grant to Accelerate Commercialization of Beltdraulic Technology
-
TrendEadvisor Launches Global Multi-Asset Platform Combining Online Investing with Social Trading
-
Global bond sell-off deepens on inflation concerns
-
India's top court drops criminal cases against protesters
-
Germany's far-right AfD promises 'boom' but economists fear worst
-
Philippine couple married in hip-deep floodwaters
-
Former England captain Stokes signs for Adelaide Strikers
-
Villa sign Senegal winger Mbaye from PSG
-
Pakistan selector and ex-captain Misbah resigns after coach sacked
-
Former Peru minister last-minute contender for UN labour agency helm
-
Shein flattens on Hong Kong debut facing global headwinds
-
Messi legacy will 'live forever', says Beckham
-
Eurozone inflation hits three-year high at 3.3% in August
-
'Literally tasting the smoke': Malaysians suffer as haze worsens
-
Man City chase Fernandez, Arsenal eye Alvarez on deadline day
-
Kyiv's defences, 'hybrid' threat from Moscow headline EU talks
-
El Nino hammering Peru anchovy fishing: industry officials
-
Oil extends gains, stocks mostly down as Trump issues fresh Iran warning
-
Mass Russian barrage kills 12 in Kyiv
-
ThinkMarkets Expands Weekend Trading Offering, Launches Weekend League Competition
-
PineX Capital Launches MetaTrader 5 as Prop Firm Expands Trading Platform Offering
-
Tibet activists accuse China of downplaying floods
-
Women survivors face sanitation woes in Nepal relief camp
-
Afghanistan war victims left 'without justice', UN says
-
Oil extends gains, stocks mixed as Trump issues fresh Iran warning
-
Iran president offers US olive branch before Putin meeting
-
Thai resort readies for US carrier's 5,000 sailors
-
China-Nepal flood toll tops 1,000 as tunnel rescue offers last hope
-
AI startup Manus says resumes independent operations
-
Japan to relax overtime regulation under workaholic PM
-
'Massive' Russian missile, drone attack on Kyiv kills 8
-
Thwarted Niger mutiny exposes junta's Russia dependence
-
Defence tech hub Munich booms as Europe rearms
-
Illegal mining ravages S.Africa's economic hub
-
Nigeria rethinks criminalisation of suicide
-
Nepal's wall of missing offers last hope after Himalayan flood
US greenlights pig kidney transplant trials
Two US biotech companies say the Food and Drug Administration has cleared them to conduct clinical trials of their gene-edited pig kidneys for human transplants.
United Therapeutics along with another company, eGenesis, have been working since 2021 on experiments implanting pig kidneys into humans: initially brain-dead patients and more recently living recipients.
Advocates hope the approach will help address the severe organ shortage. More than 100,000 people in the United States are awaiting transplants, including over 90,000 in need of kidneys.
United Therapeutics's approval, announced Monday, allows the company to advance its technology toward a licensed product if the trial succeeds.
The study authorization was hailed as a "significant step forward in our relentless mission to expand the availability of transplantable organs," by Leigh Peterson, the company's executive vice president.
The trial will initially enroll six patients with end-stage renal disease before expanding to as many as 50, United Therapeutics said in a statement. The first transplant is expected in mid-2025.
Meanwhile, rival eGenesis said it had received FDA approval in December for a separate three-patient kidney study.
"The study will evaluate patients with kidney failure who are listed for a transplant but who face a low probability of receiving a deceased donor offer within a five-year timeframe," the company said.
Xenotransplantation -- transplanting organs from one species to another -- has been a tantalizing yet elusive goal for science.
Early experiments in primates faltered, but advances in gene editing and immune system management have brought the field closer to reality.
Pigs have emerged as ideal donors: they grow quickly, produce large litters, and are already part of the human food supply.
United Therapeutics said trial patients would be monitored for life, assessing survival rates, kidney function, and the risk of zoonotic infections -- diseases that jump from animals to humans.
Currently, there is only one living human recipient of a pig organ: Towana Looney, a 53-year-old from Alabama who received a United Therapeutics kidney on November 25, 2024.
She is also the longest-surviving recipient, having lived with a pig kidney for 71 days as of Tuesday. David Bennett of Maryland received a pig heart in 2022 and survived 60 days.
K.Sutter--VB